Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 13

HOS-116352 · Präparat HOS-094447

Co-administration with PREZISTA co-administered with cobicistat is not recommended (see section 4.4). Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with 100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine etravirine Cmax ↓ 32% 200 mg twice daily can be used darunavir AUC ↑ 15% without dose adjustments. darunavir Cmin ↔ darunavir Cmax ↔ Co-administration with PREZISTA co-administered with cobicistat is not recommended (see section 4.4). Nevirapine nevirapine AUC ↑ 27% PREZISTA co-administered with 200 mg twice daily nevirapine Cmin ↑ 47% low dose ritonavir and nevirapine nevirapine Cmax ↑ 18% can be used without dose # darunavir: concentrations were adjustments. consistent with historical data (↑ nevirapine from CYP3A inhibition) Co-administration with PREZISTA co-administered with cobicistat is not recommended (see section 4.4). Rilpivirine rilpivirine AUC ↑ 130% Boosted PREZISTA and rilpivirine 150 mg once daily rilpivirine Cmin ↑ 178% can be used without dose rilpivirine Cmax ↑ 79% adjustments. darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) etravirine (HOS-088088) rilpivirine (HOS-088090) nevirapine (HOS-088064) ritonavir (HOS-084521)